{"protocolSection": {"identificationModule": {"nctId": "NCT01076075", "orgStudyIdInfo": {"id": "0431-229"}, "secondaryIdInfos": [{"id": "2010_513"}, {"id": "MK-0431-229", "type": "OTHER", "domain": "protocol number"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)", "officialTitle": "A Phase III, Randomized, Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on a Sulfonylurea in Combination With Metformin"}, "statusModule": {"statusVerifiedDate": "2017-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-06-03", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2011-07-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-01-19", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-02-24", "studyFirstSubmitQcDate": "2010-02-24", "studyFirstPostDateStruct": {"date": "2010-02-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-06-28", "resultsFirstSubmitQcDate": "2012-06-28", "resultsFirstPostDateStruct": {"date": "2012-08-07", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-05-04", "lastUpdatePostDateStruct": {"date": "2017-06-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will evaluate whether the addition of Sitagliptin treatment provides a greater decrease in A1C levels compared to placebo in participants with inadequate glycemic control on sulfonylurea and metformin combination therapy."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 427, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "placebo/pioglitazone", "type": "ACTIVE_COMPARATOR", "description": "Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): placebo to Sitagliptin 100 mg + pioglitazone 30 mg", "interventionNames": ["Drug: Comparator: placebo to Sitagliptin", "Drug: Comparator: pioglitazone", "Drug: Glimepiride or gliclazide", "Drug: Metformin", "Drug: Pioglitazone rescue therapy"]}, {"label": "Sitagliptin", "type": "EXPERIMENTAL", "description": "Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + placebo to pioglitazone", "interventionNames": ["Drug: Sitagliptin phosphate", "Drug: Comparator: placebo to pioglitazone", "Drug: Glimepiride or gliclazide", "Drug: Metformin", "Drug: Pioglitazone rescue therapy"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin phosphate", "description": "Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks", "armGroupLabels": ["Sitagliptin"], "otherNames": ["Januvia"]}, {"type": "DRUG", "name": "Comparator: placebo to pioglitazone", "description": "Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks", "armGroupLabels": ["Sitagliptin"]}, {"type": "DRUG", "name": "Comparator: placebo to Sitagliptin", "description": "Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks", "armGroupLabels": ["placebo/pioglitazone"]}, {"type": "DRUG", "name": "Comparator: pioglitazone", "description": "Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks", "armGroupLabels": ["placebo/pioglitazone"], "otherNames": ["Actos;"]}, {"type": "DRUG", "name": "Glimepiride or gliclazide", "description": "Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide", "armGroupLabels": ["Sitagliptin", "placebo/pioglitazone"]}, {"type": "DRUG", "name": "Metformin", "description": "Phase A (Weeks 0-24): stable dose, as prescribed\n\nby investigator, of metformin; Phase B (Weeks 24-\n\n54): stable dose, as prescribed by investigator, of\n\nmetformin", "armGroupLabels": ["Sitagliptin", "placebo/pioglitazone"]}, {"type": "DRUG", "name": "Pioglitazone rescue therapy", "description": "Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.", "armGroupLabels": ["Sitagliptin", "placebo/pioglitazone"], "otherNames": ["Actos"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1C (%) at Week 24", "description": "Change from baseline reflects the Week 24 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.", "timeFrame": "Baseline and Week 24"}, {"measure": "Number of Participants With One or More Adverse Events (AEs) - Week 0 to Week 54", "timeFrame": "Week 0 to Week 54"}, {"measure": "Number of Participants Discontinuing Study Drug Due to An Adverse Event", "timeFrame": "Week 0 to Week 54"}], "secondaryOutcomes": [{"measure": "Change From Baseline in 2-hour Post-Meal Glucose at Week 24", "description": "Change from baseline reflects the Week 24 value minus the baseline value. Two-hour post-meal glucose was measured following a standard meal.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in Fasting Plasma Glucose at Week 24", "description": "Change from baseline reflects the Week 24 value minus the baseline value.", "timeFrame": "Baseline to Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes mellitus\n* Hemoglobin A1C of \u22657.5% and \u226410.5%\n* Currently taking a stable dose of metformin (at least 1500 mg/day) and either glimepiride (at least 2 mg/day) or gliclazide (at least 50% of maximum registered dose) for at least 10 weeks prior to study start\n* Male, or a female who is highly unlikely to conceive\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus or ketoacidosis\n* Taking a dipeptidyl peptidase-4 (DPP-4) inhibitor (such as sitagliptin) or a glucagon-like peptide-1 (GLP-1) mimetic (such as exenatide or liraglutide) or required insulin therapy within 12 weeks prior to study start\n* On a weight loss program not in the maintenance phase or on a weight loss medication\n* History of liver disease, heart failure, heart disease, stroke, high blood pressure, blood disorders, or cancer\n* HIV positive\n* Pregnant", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "78 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "26625270", "type": "RESULT", "citation": "Moses RG, Round E, Shentu Y, Golm GT, O'neill EA, Gantz I, Engel SS, Kaufman KD, Goldstein BJ. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. J Diabetes. 2016 Sep;8(5):701-11. doi: 10.1111/1753-0407.12351. Epub 2016 Feb 3."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf\n\nhttp://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "762 participants were screened, 335 participants were excluded, and 427 participants were randomized. There was a single-blind run-in prior to randomization.", "groups": [{"id": "FG000", "title": "Sitagliptin", "description": "Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + Placebo to Pioglitazone"}, {"id": "FG001", "title": "Placebo/Pioglitazone", "description": "Phase A (Weeks 0-24): Placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): Placebo to Sitagliptin 100 mg + Pioglitazone 30 mg"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "3 participants were excluded from safety and efficacy analyses due to one site's non-compliance", "numSubjects": "213"}, {"groupId": "FG001", "comment": "2 participants were excluded from safety and efficacy analyses due to one site's non-compliance", "numSubjects": "214"}]}, {"type": "Completed Phase A", "achievements": [{"groupId": "FG000", "numSubjects": "199"}, {"groupId": "FG001", "numSubjects": "189"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "172"}, {"groupId": "FG001", "numSubjects": "167"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "41"}, {"groupId": "FG001", "numSubjects": "47"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "other", "reasons": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "19"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin", "description": "Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + Placebo to Pioglitazone"}, {"id": "BG001", "title": "Placebo/Pioglitazone", "description": "Phase A (Weeks 0-24): Placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): Placebo to Sitagliptin 100 mg + Pioglitazone 30 mg"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "210"}, {"groupId": "BG001", "value": "212"}, {"groupId": "BG002", "value": "422"}]}], "measures": [{"title": "Age, Continuous", "description": "Number of Baseline Participants for Sitagliptin (210) and for Placebo/Pioglitazone (212). Five participants (Sitagliptin: 3, Placebo/Pioglitazone: 2) were excluded from analyses due to one site's non-compliance.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.4", "spread": "9.6"}, {"groupId": "BG001", "value": "55.4", "spread": "10.2"}, {"groupId": "BG002", "value": "54.9", "spread": "9.9"}]}]}]}, {"title": "Sex: Female, Male", "description": "Number of Baseline Participants for Sitagliptin (210) and for Placebo/Pioglitazone (212). Five participants (Sitagliptin: 3, Placebo/Pioglitazone: 2) were excluded from analyses due to one site's non-compliance.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "115"}, {"groupId": "BG001", "value": "114"}, {"groupId": "BG002", "value": "229"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "95"}, {"groupId": "BG001", "value": "98"}, {"groupId": "BG002", "value": "193"}]}]}]}, {"title": "Hemoglobin A1C", "description": "Number of Baseline Participants for Sitagliptin (210) and for Placebo/Pioglitazone (212). Five participants (Sitagliptin: 3, Placebo/Pioglitazone: 2) were excluded from analyses due to one site's non-compliance.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percentage of glycosylated hemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.4", "spread": "0.8"}, {"groupId": "BG001", "value": "8.4", "spread": "0.9"}, {"groupId": "BG002", "value": "8.4", "spread": "0.8"}]}]}]}, {"title": "2-Hour Post-Meal Glucose", "description": "Number of Baseline Participants for Sitagliptin (202) and for Placebo/Pioglitazone (208). Five participants (Sitagliptin: 3, Placebo/Pioglitazone: 2) were excluded from analyses due to one site's non-compliance.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "240.3", "spread": "60.6"}, {"groupId": "BG001", "value": "243.3", "spread": "68.8"}, {"groupId": "BG002", "value": "241.8", "spread": "64.8"}]}]}]}, {"title": "Fasting Plasma Glucose", "description": "Number of Baseline Participants for Sitagliptin (210) and for Placebo/Pioglitazone (212). Five participants (Sitagliptin: 3, Placebo/Pioglitazone: 2) were excluded from analyses due to one site's non-compliance.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "164.8", "spread": "40.8"}, {"groupId": "BG001", "value": "165.0", "spread": "43.9"}, {"groupId": "BG002", "value": "164.9", "spread": "42.4"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1C (%) at Week 24", "description": "Change from baseline reflects the Week 24 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.", "populationDescription": "The Full Analysis Set Population received at least one dose of study treatment and had baseline data and at least one post-baseline treatment endpoint observation for the analysis endpoint. Missing data were imputed using last observation carried forward (LOCF). Five participants were excluded from analyses due to one site's non-compliance.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of glycosylated hemoglobin", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Phase A (Weeks 0-24): Sitagliptin 100 mg"}, {"id": "OG001", "title": "Placebo/Pioglitazone", "description": "Phase A (Week 0-24): Placebo to Sitagliptin 100 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "203"}, {"groupId": "OG001", "value": "202"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.84", "spread": "0.82", "lowerLimit": "-0.97", "upperLimit": "-0.71"}, {"groupId": "OG001", "value": "-0.16", "spread": "0.84", "lowerLimit": "-0.28", "upperLimit": "-0.03"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Pairwise comparison - Sitagliptin vs. Placebo, using the difference in the Least Squares Means.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an ANCOVA model controlling for treatment, stratum (type of sulfonylurea) and baseline value.", "paramType": "Difference in Least Squares Means", "paramValue": "-0.68", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.87", "ciUpperLimit": "-0.50"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hour Post-Meal Glucose at Week 24", "description": "Change from baseline reflects the Week 24 value minus the baseline value. Two-hour post-meal glucose was measured following a standard meal.", "populationDescription": "The Full Analysis Set Population received at least one dose of study treatment and had baseline data and at least one post-baseline treatment endpoint observation for the analysis endpoint. Missing data were imputed using last observation carried forward (LOCF). Five participants were excluded from analyses due to one site's non-compliance.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Phase A (Week 0-24): Sitagliptin 100 mg"}, {"id": "OG001", "title": "Placebo/Pioglitazone", "description": "Phase A (Week 0-24): Placebo to Sitagliptin 100 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "184"}, {"groupId": "OG001", "value": "183"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-36.8", "spread": "60.8", "lowerLimit": "-45.2", "upperLimit": "-28.4"}, {"groupId": "OG001", "value": "-3.3", "spread": "67.8", "lowerLimit": "-11.7", "upperLimit": "5.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Pairwise comparison - Sitagliptin vs. Placebo, difference in the Least Squares Means.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an ANCOVA model controlling for treatment, stratum (type of sulfonylurea) and baseline value.", "paramType": "Difference in Least Squares Means", "paramValue": "-33.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-45.3", "ciUpperLimit": "-21.7"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose at Week 24", "description": "Change from baseline reflects the Week 24 value minus the baseline value.", "populationDescription": "The Full Analysis Set Population received at least one dose of study treatment and had baseline data and at least one post-baseline treatment endpoint observation for the analysis endpoint. Missing data were imputed using last observation carried forward (LOCF). Five participants were excluded from analyses due to one site's non-compliance.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Phase A (Week 0-24): Sitagliptin 100 mg"}, {"id": "OG001", "title": "Placebo/Pioglitazone", "description": "Phase A (Week 0-24): Placebo to Sitagliptin 100 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "204"}, {"groupId": "OG001", "value": "203"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.2", "lowerLimit": "-18.8", "upperLimit": "-7.7"}, {"groupId": "OG001", "value": "5.3", "lowerLimit": "-0.2", "upperLimit": "10.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Pairwise comparison - Sitagliptin vs. Placebo, using the difference in the Least Squares Means.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Based on an ANCOVA model controlling for treatment, stratum (type of sulfonylurea) and baseline value.", "paramType": "Difference in Least Squares Means", "paramValue": "-18.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.4", "ciUpperLimit": "-10.7"}]}, {"type": "PRIMARY", "title": "Number of Participants With One or More Adverse Events (AEs) - Week 0 to Week 54", "populationDescription": "The All Patients as Treated Population took at least one dose of study drug. Participants received glycemic rescue medication if they met specific glycemic goals up to Week 24. Adverse events include those that occurred prior to a receiving rescue medication. Five participants were excluded from analyses due to 1 site's non-compliance.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 0 to Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + Placebo to Pioglitazone"}, {"id": "OG001", "title": "Placebo/Pioglitazone", "description": "Phase A (Weeks 0-24: Placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): Placebo to Sitagliptin 100 mg + Pioglitazone 30 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "210"}, {"groupId": "OG001", "value": "212"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "122"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants Discontinuing Study Drug Due to An Adverse Event", "populationDescription": "The All Patients as Treated Population took at least 1 dose of study drug. Participants received glycemic rescue medication if they met specific glycemic goals up to Week 24. Participants discontinued due to adverse events are reported regardless of rescue medication. Five participants were excluded from analyses due to 1 site's non-compliance.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 0 to Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + Placebo to Pioglitazone"}, {"id": "OG001", "title": "Placebo/Pioglitazone", "description": "Phase A (Weeks 0-24: Placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): Placebo to Sitagliptin 100 mg + Pioglitazone 30 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "210"}, {"groupId": "OG001", "value": "212"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Week 0 to Week 54", "description": "All Patients as Treated Population took at least 1 dose of study drug. Participants received glycemic rescue medication if they met specific glycemic goals up to Week 24. Serious AEs (SAEs) are reported regardless of rescue medication. Other AEs are those that occurred prior to rescue medication. Five participants were excluded from analyses.", "eventGroups": [{"id": "EG000", "title": "Sitagliptin", "description": "Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + Placebo to Pioglitazone", "seriousNumAffected": 6, "seriousNumAtRisk": 210, "otherNumAffected": 49, "otherNumAtRisk": 210}, {"id": "EG001", "title": "Placebo/Pioglitazone", "description": "Phase A (Weeks 0-24): Placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): Placebo to Sitagliptin 100 mg + Pioglitazone 30 mg", "seriousNumAffected": 9, "seriousNumAtRisk": 212, "otherNumAffected": 44, "otherNumAtRisk": 212}], "seriousEvents": [{"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 212}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 212}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 212}]}, {"term": "Abscess limb", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 212}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 212}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 212}]}, {"term": "Gangrene", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 212}]}, {"term": "Tooth abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 212}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 212}]}, {"term": "Joint dislocation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 212}]}, {"term": "Skull fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 212}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 212}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 212}]}, {"term": "Bladder neck obstruction", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 212}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 212}]}, {"term": "Nasal inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 212}]}, {"term": "Pneumonitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 212}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 212}]}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 14, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 16, "numAffected": 15, "numAtRisk": 212}]}, {"term": "Hypoglcaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 187, "numAffected": 38, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 148, "numAffected": 31, "numAtRisk": 212}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Australia", "Hong Kong", "Hungary", "India", "Korea, Republic of", "Malaysia", "Philippines", "Russian Federation", "Taiwan"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077205", "term": "Pioglitazone"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "C000057619", "term": "Glimepiride"}, {"id": "D000005907", "term": "Gliclazide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M1693", "name": "Pioglitazone", "asFound": "Registry", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M9018", "name": "Gliclazide", "asFound": "Boys", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}